Signaturefd, LLC Arvinas, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 573 shares of ARVN stock, worth $10,932. This represents 0.0% of its overall portfolio holdings.

Number of Shares

573

Previous 573 -0.0%

Holding current value

$10,932

Previous $15,000 6.67%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$24.46 - $40.4 $391 - $646	-16 Reduced 2.72%	573 $15,000
Q1 2024 May 03, 2024	BUY	$36.38 - $52.31 $582 - $836	16 Added 2.79%	589 $24,000
Q4 2023 Jan 31, 2024	BUY	$14.19 - $42.33 $7,109 - $21,207	501 Added 695.83%	573 $23,000
Q3 2023 Nov 03, 2023	BUY	$19.64 - $28.21 $707 - $1,015	36 Added 100.0%	72 $1,000
Q2 2023 Aug 01, 2023	BUY	$21.73 - $31.43 $217 - $314	10 Added 38.46%	36 $0
Q1 2023 Apr 28, 2023	SELL	$26.15 - $37.26 $627 - $894	-24 Reduced 48.0%	26 $0
Q4 2022 Jan 27, 2023	SELL	$32.47 - $57.24 $1,818 - $3,205	-56 Reduced 52.83%	50 $1,000
Q3 2022 Nov 08, 2022	BUY	$41.87 - $57.99 $4,438 - $6,146	106 New	106 $5,000
Q2 2022 Aug 10, 2022	SELL	$36.01 - $74.24 $360 - $742	-10 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$60.27 - $81.57 $120 - $163	2 Added 25.0%	10 $1,000
Q4 2021 Jan 25, 2022	BUY	$65.85 - $96.21 $131 - $192	2 Added 33.33%	8 $1,000
Q2 2021 Jul 26, 2021	SELL	$60.45 - $84.26 $362 - $505	-6 Reduced 50.0%	6 $0
Q1 2021 Apr 30, 2021	BUY	$58.19 - $91.37 $698 - $1,096	12 New	12 $1,000

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account